Press Releases

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES NEW SERVICE OFFERING TO SUPPORT DEVELOPMENT AND cGMP MONOCLONAL ANTIBODY PRODUCTION

March 1, 2017

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES NEW SERVICE OFFERING TO SUPPORT DEVELOPMENT AND cGMP MONOCLONAL ANTIBODY PRODUCTION

Read More

EXPANDING FAST-GROWING CONTRACT DEVELOPMENT AND MANUFACTURING BUSINESS FOR BIOPHARMACEUTICALS

February 28, 2017

Aiming to achieve 100 billion yen in revenue by FY2024/March

Read More

Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility for use by its Contract Development and Manufacturing Customers

June 6, 2016

FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced that it is in the process of establishing a long-term collaboration with MSD, a global biopharmaceutical company known as Merck in the U.S. and Canada, to invest in and operate a large-scale microbial-biologics facility for supply of active pharmaceutical ingredient (API) to its customers.

Read More
Triangle Park, NC

FUJIFILM Diosynth Biotechnologies Opens New Laboratory Facility in Research Triangle Park, NC

May 9, 2016

Construction now complete on new 62,000 square foot facility

Read More

Fujifilm initiates a Phase I clinical trial in the United States of the anti-cancer agent “FF-21101” in Patients with advanced solid tumors such as Lung cancer.

January 14, 2016

FUJIFILM Corporation (President: Shigehiro Nakajima) has begun a Phase I clinical trial of its anti-cancer agent FF-21101 in the United States in patients with advanced solid tumors such as lung cancers in 12 January. The trial is carried out at The University of Texas MD Anderson Cancer Center*, one of the world's most distinguished facilities for cancer research and treatment.

Read More

Fujifilm Diosynth Biotechnologies breaks ground on laboratory facility in Research Triangle Park, NC

January 13, 2015

Construction begins on new 62,000 square foot facility

Read More

MBE for Fujifilm Diosynth Biotechnologies’ Subhash Chaudhary in new years’ honours list

December 31, 2014

FUJIFILM Diosynth Biotechnologies is delighted to announce that Subhash Chaudhary, Director of Strategic Projects, has been awarded an MBE in the Queen's New Year Honours.

Read More

Fujifilm completes acquisition of Kalon Biotherapeutics

December 18, 2014

Acquisition Enhances Texas' Growing Reputation as a Global Biotechnology Leader

Read More

Fujifilm Diosynth Biotechnologies announces the launch of its ‘Apollo™’ mammalian expression platform

October 9, 2014

FUJIFILM Diosynth Biotechnologies has announced the launch of its new mammalian expression platform, which it has named 'Apollo™'.

Read More

Fujifilm chooses ambr250 mini bioreactor system to optimise its fermentation process development

September 16, 2014

FUJIFILM Diosynth Biotechnologies chooses ambr250 System for Optimising Microbial Fermentation To Rapidly Develop Robust Scale-up Processes for Biopharmaceutical Production

Read More

Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile

August 24, 2014

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of SYN-004, Synthetic Biologics' proprietary oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infections.

Read More

FUJIFILM Diosynth Biotechnologies expands cell culture manufacturing capacity with addition of two new 2,000L single-use bioreactors

August 19, 2014

FUJIFILM Diosynth Biotechnologies has announced continued expansion of its cell culture manufacturing capabilities with the addition of two 2000L single-use bioreactors. One each of these is being installed at the company's sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.

Read More

FUJIFILM Disoynth Biotechnologies continues Expansion of R&D Facilities including addition of Latest High Throughput Equipment

June 23, 2014

Fujifilm Diosynth Biotechnologies has announced continued expansion of its process development capabilities with the investment of over US$5.6m in new laboratories and equipment at both its Billingham, UK and Research Triangle Park (RTP), NC, USA sites. This includes the first TAP ambr250™ automated bioreactor system for microbial fermentations to be commercially installed in a CDMO at the company’s Billingham, UK site. This investment further demonstrates the company’s commitment to use High Throughput technology and design of experiments to benefit its customers by rapid development of robust scalable processes for their biopharmaceutical production.

Read More

FUJIFILM Diosynth Biotechnologies’ UK site receives MHRA Manufacturing License

October 9, 2013

FUJIFILM Diosynth Biotechnologies has announced that it has received a renewal of its Manufacturer's Licence from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The Licence authorises commercial manufacturing at the company's Billingham, UK site, and was received with zero critical or major observations.

Read More

FUJIFILM Diosynth Biotechnologies’ Opens New Manufacturing Facility

October 2, 2013

FUJIFILM Diosynth Biotechnologies today formally opened its new mammalian cell culture cGMP manufacturing facility at a ceremony performed by HRH The Duke of Gloucester KG GCVO, a member of the UK Royal Family.

Read More

FUJIFILM Diosynth Biotechnologies to Evaluate of Synthetic Biologics’ Propietary Beta-Lactamase Enzyme, SYN-004

July 18, 2013

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today the initiation of the manufacturing process of the Company's proprietary beta-lactamase enzyme (SYN-004) to target the prevention of Clostridium difficile (C. difficile or C. diff) infections. Pursuant to an agreement with FUJIFILM Diosynth Biotechnologies UK Limited (FUJIFILM), the initial phase of the SYN-004 manufacturing process is underway with the evaluation of beta-lactamase protein expression in FUJIFILM's pAVEway™ platform. SYN-004 will be evaluated for production cell line yields as well as biological activity of the enzyme product.

Read More

FUJFILM Diosynth Biotechnologies commissions new cell banking facility at Billingham, UK Site

April 22, 2013

FUJIFILM Diosynth Biotechnologies has announced that it has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.

Read More

FUJIFILM Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates

October 24, 2012

FUJIFILM Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

Read More

FUJIFILM Diosynth Biotechnologies expands R&D Capabilities at its Billingham, UK Site

March 29, 2012

FUJIFILM Diosynth Biotechnologies has completed the first phase of a 3m ($4.5m) investment in new equipment and laboratories at its Billingham, UK site. This expansion reinforces the commitment to lead the global Biologics CMO industry through continuous innovation and implementation of new technologies, service delivery and quality, as announced by Japan-based parent company, FUJIFILM Corporation.

Read More

FUJIFILM Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Novel Anti-Staph Biologic

October 25, 2011

FUJIFILM Diosynth Biotechnologies and ContraFect Corporation announced today that they have signed a contract to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysin. CF-301 is ContraFect’s lead compound and displays potent activity against all forms of Staph infections, including methicillin-resistant (MRSA) and vancomycin-resistant strains (VISA/VRSA).

Read More

FUJIFILM Diosynth Biotechnologies Expands Mammalian Cell Culture Capacity

June 1, 2011

FUJIFILM Diosynth Biotechnologies is expanding its existing contract manufacturing capabilities with the addition of a 1,000L Xcellerex Single-Use Bioreactor to its RTP, North Carolina facility. This expansion reinforces the commitment to lead the global Biologics CMO industry through continuous innovation and implementation of new technologies, service delivery and quality, as announced by Japan-based parent company, FUJIFILM Corporation.

Read More

FUJIFILM Completes Acquisition of Merck Biomanufacturing Network

April 1, 2011

FUJIFILM Diosynth Biotechnologies has been announced as the new name for the former Merck BioManufacturing Network (known as MSD BioManufacturing Network outside United States and Canada) following completion of its acquisition today by FUJIFILM Corporation of Japan.

Read More

FUJIFILM to Acquire Merck Biomanufacturing Network

February 28, 2011

FUJIFILM purchases Merck contract manufacturing and service subsidiaries Diosynth and MSD Billingham

Read More

MSD Signs Deal with ThromboGenics for Long-term Commercial Supply of Microplasmin

September 30, 2010

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has signed a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial needs for bulk drug substance of this novel therapeutic agent.

Read More